Association between the initial dose urate-lowering drugs and gout flares in adult males with gout
Authors' conclusion
This observational study demonstrated that initial low-dose febuxostat was equally effective in preventing gout flares as colchicine prophylaxis, while initial high-dose febuxostat alone was associated with an increased risk of gout flares.
Study context
- Population
- Adult males with gout during initial introduction of urate-lowering therapy (ULT), single-centre gout cohort, August 2017 to October 2020
- Participants
- 582 males
- Exposure
- Initial low-dose or high-dose febuxostat alone vs colchicine prophylaxis
- Outcome
- Association of initial dose febuxostat with gout flares
- Follow-up
- 6 weeks
Methodological detailssingle-centre, consecutive patients, Cox hazard models with inverse probability of treatment weighting (IPTW)
- Single-centre
- Consecutive patients
- Cox hazard models with IPTW
Main finding
As reported in the abstract
Gout flares
Each group vs colchicine prophylaxisHazard ratio (95% CI)
Low-dose febuxostat
1.26(0.58–2.72)
High-dose febuxostat
3.08(1.34–7.07)
Observational data: associations, not effects.
Further findings
Gout flares, whole cohort · 6 weeks
- Patients with gout flares
- 71 (12.2%)
Original publication
Association between the initial dose urate-lowering drugs and gout flares in adult males with gout. Rheumatology (Oxford). Published 23 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →